Señales en vivo de ABVC | Maximiza tus Ganancias con Getagraph.com

COMPRAR 116595 min ago

@ $1.300

Emitido: 8 feb 2024 @ 13:07

Retorno: 7.78%

Señal anterior: feb 7 - 09:30

Señal anterior: Vender

Retorno: -7.80 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 13:21):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
Volumen de hoy	1.55M
Volumen promedio	1.09M
Capitalización de mercado	14.80M
EPS	$0 ( 2024-03-29 )
Próxima fecha de ganancias	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00900 (0.64%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

Volumen Correlación

Largo: -0.11 (neutral)

Corto: -0.49 (neutral)

Signal:(64.658) Neutral

AMERICAN BRIVISION Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AMERICAN BRIVISION Correlación - Moneda/Commodity

-0.76
( moderate negative )

-0.68
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

0.73
( moderate )

AMERICAN BRIVISION Finanzas

Annual	2023
Ingresos:	$152 430
Beneficio Bruto:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
Ingresos:	$152 430
Beneficio Bruto:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
Ingresos:	$969 783
Beneficio Bruto:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
Ingresos:	$355 797
Beneficio Bruto:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.